<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-75031</identifier>
<setSpec>1130-1406</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">The role of anidulafungin therapy in solid organ transplant recipients</dc:title>
<dc:description xml:lang="en">Anidulafungin is a new echinocandin recently approved for the treatment ofesophageal candidiasis, candidemia and other forms of invasive candidiasis,such as peritonitis and intra-abdominal abscesses in non-neutropenic patients.It is fungicidal against Candida spp and fungistatic against Aspergillus spp.It is active against Pneumocystis jirovecii. In contrast, anidulafungin does nothave activity against Cryptococcus neoformans, Zygomycetes or molds, otherthan Aspergillus spp. The drug is well tolerated, even in patients with renal orhepatic impairment. In contrast to other echinocandins, it does notsignificantly interfere with the cytochrome P450 pathway and has a lowdrug&#150;drug interaction profile, including calcineurinic agents and other drugsused in transplant recipients. So far, anidulafungin appears to have anexcellent safety profile with few adverse events and it promises a specialconsideration in the management of fungal infections happening in transplantrecipients(AU)</dc:description>
<dc:creator>Fortún Abete, Jesús</dc:creator>
<dc:creator>Martín-Dávila, Pilar</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La anidulafungina es una nueva equinocandina aceptada para el tratamientode candidiasis esofágica, candidemia y otras formas de candidiasis, comoperitonitis o abscesos intraabdominales en pacientes no neutropénicos.Como las otras equinocandinas, posee una elevada actividad fungicida frentea la mayoría de las especies de Candida y es fungistático frente aAspergillus spp. También tiene buena actividad frente a Pneumocystis jiroveciiy es poco activa frente a Cryptococcus neoformans, mucorales y otroshongos filamentosos diferentes a Aspergillus spp. Presenta ausencia o mínimatoxicidad renal y/o hepática y, a diferencia de otras equinocandinas y azoles,no sufre metabolización asociada con el citocromo P450. Por tanto, carecede interacciones medicamentosas con los calcineurínicos y otros fármacosutilizados en los pacientes trasplantados. Esta característica permite a laanidulafungina posicionarse como un antifúngico especialmente interesante eneste tipo de pacientes(AU)</dc:description>
<dc:source>Rev Iberoam Micol;25(2): 129-133, 2008. tab</dc:source>
<dc:identifier>ibc-75031</dc:identifier>
<dc:title xml:lang="es">Potencial de anidulafungina en la terapia de receptores de trasplante de órgano sólido</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d2209^s22057</dc:subject>
<dc:subject>^d52786^s22079</dc:subject>
<dc:subject>^d9282^s22021</dc:subject>
<dc:subject>^d29074^s22020</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d1235^s22057</dc:subject>
<dc:subject>^d3470^s22057</dc:subject>
<dc:subject>^d9373^s22057</dc:subject>
<dc:type>article</dc:type>
<dc:date>200800</dc:date>
</metadata>
</record>
</ibecs-document>
